Hong Kong, Shanghai & Florham Park, NJ — Monday, May 2, 2022: Hutchmed (China) Limited (“Hutchmed” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) announced that the U.S. Food and Drug Administration (“FDA”…Original Article
Hutchmed Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
